The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Antibody Drug Conjugates for Cancer Therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1776 · Cited by 1,676
Paul Ehrlich's magic bullet concept: 100 years of progress
Strebhardt, K., & Ullrich, A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2394 · Cited by 1,457
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt.1480 · Cited by 1,382
Self-citationEffects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M. C., Lenox, J., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., Zabinski, R. F., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0789 · Cited by 1,247
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt832 · Cited by 1,206
Shen, B.-Q., Xu, K., Liu, L., Raab, H., Bhakta, S., Kenrick, M., Parsons-Reponte, K. L., Tien, J., Yu, S.-F., Mai, E., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2108 · Cited by 1,008
Self-citationCrystal Structures of Human Topoisomerase I in Covalent and Noncovalent Complexes with DNA
Redinbo, M. R., Stewart, L., Kuhn, P., Champoux, J. J., & Hol, W. G. J. (1998) · Science · doi:10.1126/science.279.5356.1504 · Cited by 889
Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., & Sato, K. (1991) · PubMed · Cited by 865
Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs
Chari, R. V. J. (2008) · Accounts of Chemical Research · doi:10.1021/ar700108g · Cited by 815
Burris, H. A., Rugo, H. S., Vukelja, S. J., Vogel, C. L., Borson, R. A., Limentani, S., Tan-Chiu, E., Krop, I. E., Michaelson, R. A., Girish, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.5865 · Cited by 764
Site-specific antibody drug conjugates for cancer therapy
Panowski, S., Bhakta, S., Raab, H., Polakis, P., & Junutula, J. R. (2014) · mAbs · doi:10.4161/mabs.27022 · Cited by 676
Self-citationSynthesis of site-specific antibody-drug conjugates using unnatural amino acids
Axup, J. Y., Bajjuri, K. M., Ritland, M., Hutchins, B. M., Kim, C. H., Kazane, S. A., Halder, R., Forsyth, J. S., Santidrian, A. F., Stafin, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211023109 · Cited by 596
The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10
Pettit, G. R., Kamano, Y., Herald, C. L., Tuinman, A. A., Boettner, F. E., Kizu, H., Schmidt, J. M., Baczynskyj, L., Tomer, K. B., & Bontems, R. J. (1987) · Journal of the American Chemical Society · doi:10.1021/ja00256a070 · Cited by 583
Calicheamicin γ 1 I : an Antitumor Antibiotic That Cleaves Double-Stranded DNA Site Specifically
Zein, N., Sinha, A. M., McGahren, W. J., & Ellestad, G. A. (1988) · Science · doi:10.1126/science.3240341 · Cited by 565
ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization
Kallioniemi, O. P., Kallioniemi, A., Kurisu, W., Thor, A., Chen, L. C., Smith, H. S., Waldman, F. M., Pinkel, D., & Gray, J. W. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5321 · Cited by 555
Lee, M. D., Dunne, T. S., Chang, C. C., Ellestad, G. A., Siegel, M. M., Morton, G. O., McGahren, W. J., & Borders, D. B. (1987) · Journal of the American Chemical Society · doi:10.1021/ja00245a051 · Cited by 523
Doronina, S. O., Mendelsohn, B. A., Bovee, T. D., Cerveny, C. G., Alley, S. C., Meyer, D. L., Oflazoglu, E., Toki, B. E., Sanderson, R. J., Zabinski, R. F., et al. (2006) · Bioconjugate Chemistry · doi:10.1021/bc0502917 · Cited by 515
Mechanism of Action of Camptothecin
Liu, L. F., Duann, P., Lin, C., D'Arpa, P., & Wu, J. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb26375.x · Cited by 508
Strop, P., Liu, S.-H., Dorywalska, M., Delaria, K., Dushin, R. G., Tran, T.-T., Ho, W.-H., Farias, S., Casas, M. G., Abdiche, Y., et al. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.01.010 · Cited by 505
Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates
Alley, S. C., Benjamin, D. R., Jeffrey, S. C., Okeley, N. M., Meyer, D. L., Sanderson, R. J., & Senter, P. D. (2008) · Bioconjugate Chemistry · doi:10.1021/bc7004329 · Cited by 479
Kovtun, Y. V., Audette, C. A., Ye, Y., Xie, H., Ruberti, M. F., Phinney, S. J., Leece, B. A., Chittenden, T., Blättler, W. A., & Goldmacher, V. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3973 · Cited by 479
Mechanism of Action of Camptothecin
LIU, L. F., DESAI, S. D., LI, T., MAO, Y., SUN, M., & SIM, S. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb07020.x · Cited by 476
Tumor inhibitors. LXXIII. Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus
Kupchan, S. M., Komoda, Y., Court, W. A., Thomas, G. J., Smith, R. M., Karim, A., Gilmore, C. J., Haltiwanger, R. C., & Bryan, R. F. (1972) · Journal of the American Chemical Society · doi:10.1021/ja00759a054 · Cited by 434
Lee, M. D., Dunne, T. S., Siegel, M. M., Chang, C. C., Morton, G. O., & Borders, D. B. (1987) · Journal of the American Chemical Society · doi:10.1021/ja00245a050 · Cited by 392
Kung Sutherland, M. S., Walter, R. B., Jeffrey, S. C., Burke, P. J., Yu, C., Kostner, H., Stone, I., Ryan, M. C., Sussman, D., Lyon, R. P., et al. (2013) · Blood · doi:10.1182/blood-2013-03-491506 · Cited by 391
Hassan, R., Bullock, S., Premkumar, A., Kreitman, R. J., Kindler, H., Willingham, M. C., & Pastan, I. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0869 · Cited by 379
Krop, I. E., LoRusso, P., Miller, K. D., Modi, S., Yardley, D., Rodriguez, G., Guardino, E., Lu, M., Zheng, M., Girish, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.5902 · Cited by 366
Recent Developments in the Maytansinoid Antitumor Agents
Cassady, J. M., Chan, K. K., Floss, H. G., & Leistner, E. (2004) · CHEMICAL & PHARMACEUTICAL BULLETIN · doi:10.1248/cpb.52.1 · Cited by 342
Mesothelin targeted cancer immunotherapy
Hassan, R., & Ho, M. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2007.08.028 · Cited by 340
Starodub, A. N., Ocean, A. J., Shah, M. A., Guarino, M. J., Picozzi, V. J., Vahdat, L. T., Thomas, S. S., Govindan, S. V., Maliakal, P. P., Wegener, W. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3321 · Cited by 340
Garg, A., & Balthasar, J. P. (2007) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-007-9065-1 · Cited by 327
Dolastatin 10, a powerful cytostatic peptide derived from a marine animal
Bai, R., Petit, G. R., & Hamel, E. (1990) · Biochemical Pharmacology · doi:10.1016/0006-2952(90)90613-p · Cited by 321
Molecular Characterization and Inhibition of Amanitin Uptake into Human Hepatocytes
Letschert, K., Faulstich, H., Keller, D., & Keppler, D. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfj141 · Cited by 298
Vascular Factors in Cognitive Impairment‐Where Are We Now?
HACHINSKI, V., & MUNOZ, D. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06343.x · Cited by 297
Dennler, P., Chiotellis, A., Fischer, E., Brégeon, D., Belmant, C., Gauthier, L., Lhospice, F., Romagne, F., & Schibli, R. (2014) · Bioconjugate Chemistry · doi:10.1021/bc400574z · Cited by 292
Dornan, D., Bennett, F., Chen, Y., Dennis, M., Eaton, D., Elkins, K., French, D., Go, M. A. T., Jack, A., Junutula, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-02-205500 · Cited by 273
Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer
Tolcher, A. W., Sugarman, S., Gelmon, K. A., Cohen, R., Saleh, M., Isaacs, C., Young, L., Healey, D., Onetto, N., & Slichenmyer, W. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.478 · Cited by 271
Corut, A., Senyigit, A., Ugur, S. A., Altin, S., Ozcelik, U., Calisir, H., Yildirim, Z., Gocmen, A., & Tolun, A. (2006) · The American Journal of Human Genetics · doi:10.1086/508263 · Cited by 271
Immunoconjugates containing novel maytansinoids: promising anticancer drugs.
CHARI, R. V. J., Martell, B., Gross, J. L., Cook, S., Shah, S. A., Blättler, W. A., McKenzie, S. J., & Goldmacher, V. S. (1992) · PubMed · Cited by 266
Erickson, H. K., Widdison, W. C., Mayo, M. F., Whiteman, K., Audette, C., Wilhelm, S. D., & Singh, R. (2010) · Bioconjugate Chemistry · doi:10.1021/bc900315y · Cited by 246
Recent Trends in Targeted Anticancer Prodrug and Conjugate Design
Singh, Y., Palombo, M., & Sinko, P. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708785132997 · Cited by 242
Hinman, L. M., Hamann, P. R., Wallace, R., Menendez, A. T., Durr, F. E., & Upeslacis, J. (1993) · PubMed · Cited by 236
Lopus, M., Oroudjev, E., Wilson, L., Wilhelm, S., Widdison, W., Chari, R., & Jordan, M. A. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0644 · Cited by 232
Hamann, P. R., Hinman, L. M., Beyer, C. F., Lindh, D., Upeslacis, J., Flowers, D. A., & Bernstein, I. (2002) · Bioconjugate Chemistry · doi:10.1021/bc0100206 · Cited by 230
Kellogg, B. A., Garrett, L., Kovtun, Y., Lai, K. C., Leece, B., Miller, M., Payne, G., Steeves, R., Whiteman, K. R., Widdison, W., et al. (2011) · Bioconjugate Chemistry · doi:10.1021/bc100480a · Cited by 219
Boger, D. L., & Johnson, D. S. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.9.3642 · Cited by 217
Drake, P. M., Albers, A. E., Baker, J., Banas, S., Barfield, R. M., Bhat, A. S., de Hart, G. W., Garofalo, A. W., Holder, P., Jones, L. C., et al. (2014) · Bioconjugate Chemistry · doi:10.1021/bc500189z · Cited by 212
Tolcher, A. W., Ochoa, L., Hammond, L. A., Patnaik, A., Edwards, T., Takimoto, C., Smith, L., de Bono, J., Schwartz, G., Mays, T., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.137 · Cited by 206 · cited 9×
“Of the 30 patients with detectable plasmaCanAg levels, 25 experienced rapid reductions to undetectable levels after the first dose of the ADC, which was maintained for up to 21 days in the majority of the patients.”
BackgroundInfluentialGregson, S. J., Howard, P. W., Hartley, J. A., Brooks, N. A., Adams, L. J., Jenkins, T. C., Kelland, L. R., & Thurston, D. E. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm001064n · Cited by 202
van der Lee, M. M. C., Groothuis, P. G., Ubink, R., van der Vleuten, M. A. J., van Achterberg, T. A., Loosveld, E. M., Damming, D., Jacobs, D. C. H., Rouwette, M., Egging, D. F., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0881-t · Cited by 201
Moldenhauer, G., Salnikov, A. V., Lüttgau, S., Herr, I., Anderl, J., & Faulstich, H. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs140 · Cited by 199
Auristatin Antibody Drug Conjugate Physical Instability and the Role of Drug Payload
Adem, Y. T., Schwarz, K. A., Duenas, E., Patapoff, T. W., Galush, W. J., & Esue, O. (2014) · Bioconjugate Chemistry · doi:10.1021/bc400439x · Cited by 194
Ojima, I. (2008) · Accounts of Chemical Research · doi:10.1021/ar700093f · Cited by 191
Chu, P. G., & Arber, D. A. (2001) · Applied Immunohistochemistry & Molecular Morphology · doi:10.1097/00129039-200106000-00001 · Cited by 190
The development of pyrrolobenzodiazepines as antitumour agents
Hartley, J. A. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.573477 · Cited by 175
Younes, A., Kim, S., Romaguera, J., Copeland, A., Farial, S. D. C., Kwak, L. W., Fayad, L., Hagemeister, F., Fanale, M., Neelapu, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.4403 · Cited by 170
Younes, A., Yasothan, U., & Kirkpatrick, P. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3629 · Cited by 170
Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies
Shor, B., Gerber, H., & Sapra, P. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.09.014 · Cited by 149
Drug‐conjugated antibodies for the treatment of cancer
Lambert, J. M. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12044 · Cited by 148
Galsky, M. D., Eisenberger, M., Moore-Cooper, S., Kelly, W. K., Slovin, S. F., DeLaCruz, A., Lee, Y., Webb, I. J., & Scher, H. I. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0532 · Cited by 145
Clinical status of anti-cancer agents derived from marine sources
Singh, R., Sharma, M., Joshi, P., & Rawat, D. (2008) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152008785133074 · Cited by 143
Discovery of Cytotoxic Dolastatin 10 Analogues with N-Terminal Modifications
Maderna, A., Doroski, M., Subramanyam, C., Porte, A. M., Leverett, C. A., Vetelino, B. C., Chen, Z., Risley, H., Parris, K. D., Pandit, J., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501649k · Cited by 143
The Cyanobacterial Origin of Potent Anticancer Agents Originally Isolated from Sea Hares
Luesch, H., Harrigan, G. G., Goetz, G. H., & Horgen, F. D. (2002) · Current Medicinal Chemistry · doi:10.2174/0929867023369051 · Cited by 139
Hartley, J. A., Spanswick, V. J., Brooks, N. A., Clingen, P. H., McHugh, P. J., Hochhauser, D., Pedley, R. B., Kèlland, L. R., Alley, M. C., Schultz, R. J., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2941 · Cited by 138
Tannir, N. M., Forero, A., Ramchandren, R., Pal, S. K., Ansell, S. M., Infante, J. R., de Vos, S., Hamlin, P. A., Kim, S. K., Whiting, N. C., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0151-0 · Cited by 128
Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors
Annunziata, C. M., Kohn, E. C., LoRusso, P. M., Houston, N. D., Coleman, R. L., Buzoianu, M., Robbie, G. J., & Lechleider, R. J. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9801-2 · Cited by 121
Metabolic Engineering of Monoclonal Antibody Carbohydrates for Antibody–Drug Conjugation
Okeley, N. M., Toki, B. E., Zhang, X., Jeffrey, S. C., Burke, P., Alley, S. C., & Senter, P. D. (2013) · Bioconjugate Chemistry · doi:10.1021/bc4002695 · Cited by 120
Trastuzumab Emtansine (T-DM1): A Novel Agent for Targeting HER2+ Breast Cancer
Burris, H. A., Tibbitts, J., Holden, S. N., Sliwkowski, M. X., & Phillips, G. D. L. (2011) · Clinical Breast Cancer · doi:10.1016/j.clbc.2011.03.018 · Cited by 120
Wright, A. M., Sato, Y., Okada, T., Chang, K. H., Endo, T., & Morrison, S. L. (2000) · Glycobiology · doi:10.1093/glycob/10.12.1347 · Cited by 119
Localisation and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer
Ford, C. H. J., Newman, C. E., Johnson, J. R., et al. (1983) · British Journal of Cancer · doi:10.1038/bjc.1983.4 · Cited by 118
Pillow, T. H., Tien, J., Parsons-Reponte, K., Bhakta, S., Li, H., Staben, L. R., Li, G., Chuh, J., Fourie-O’Donohue, A., Darwish, M., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500552c · Cited by 107
Self-citationTrastuzumab Emtansine: A Novel Antibody–Drug Conjugate for HER2-Positive Breast Cancer
Krop, I. E., & Winer, E. P. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0541 · Cited by 105
Molecularly Defined Antibody Conjugation through a Selenocysteine Interface
Höfer, T., Skeffington, L. R., Chapman, C. M., & Rader, C. M. (2009) · Biochemistry · doi:10.1021/bi901744t · Cited by 104
Expression of type II Na-Picotransporter in alveolar type II cells
Traebert, M., Hattenhauer, O., Murer, H., Kaissling, B., & Biber, J. (1999) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.1999.277.5.l868 · Cited by 104
Tan, M., Mol, G. C., van Rooden, C. J., Klok, F. A., Westerbeek, R. E., del Sol, A. I., van de Ree, M. A., Roos, A., & Huisman, M. V. (2014) · Blood · doi:10.1182/blood-2014-04-566380 · Cited by 103
Use of Tissue Cross-reactivity Studies in the Development of Antibody-based Biopharmaceuticals
Leach, M. W., Halpern, W., Johnson, C. W., Rojko, J. L., MacLachlan, T. K., Chan, C. M., Galbreath, E. J., Ndifor, A. M., Blanset, D. L., Polack, E., et al. (2010) · Toxicologic Pathology · doi:10.1177/0192623310382559 · Cited by 101
Ott, P. A., Hamid, O., Pavlick, A. C., Kluger, H. M., Kim, K. B., Boasberg, P. D., Simantov, R., Crowley, E. M., Green, J. A., Hawthorne, T. R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8115 · Cited by 97
Chen, Y., Clark, S., Wong, T., Chen, Y., Chen, Y., Dennis, M. S., Luis, E., Zhong, F., Bheddah, S., Koeppen, H., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4512 · Cited by 94
Self-citationZuberbühler, K., Casi, G., Bernardes, G. J. L., & Neri, D. (2012) · Chemical Communications · doi:10.1039/c2cc32412a · Cited by 92
Elias, D. J., Hirschowitz, L., Kline, L. E., Kroener, J. F., Dillman, R. O., Walker, L. E., Robb, J. A., & Timms, R. M. (1990) · PubMed · Cited by 85
Li, D., Poon, K. A., Yu, S., Dere, R. C., Go, M., Lau, J., Zheng, B., Elkins, K., Danilenko, D. M., Kozak, K. R., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1173 · Cited by 85
Tomihari, M., Hwang, S., Chung, J., Cruz Jr., P. D., & Ariizumi, K. (2009) · Experimental Dermatology · doi:10.1111/j.1600-0625.2008.00830.x · Cited by 84
Targeting CD22 in B-cell Malignancies: Current Status and Clinical Outlook
Sullivan-Chang, L., OʼDonnell, R. T., & Tuscano, J. M. (2013) · BioDrugs · doi:10.1007/s40259-013-0016-7 · Cited by 80
Site-specific chemical modification of antibody fragments using traceless cleavable linkers
Bernardes, G. J. L., Steiner, M., Hartmann, I., Neri, D., & Casi, G. (2013) · Nature Protocols · doi:10.1038/nprot.2013.121 · Cited by 76
RARα2 expression confers myeloma stem cell features
Yang, Y., Shi, J., Tolomelli, G., Xu, H., Xia, J., Wang, H., Zhou, W. H., Zhou, Y., Das, S., Gu, Z., et al. (2013) · Blood · doi:10.1182/blood-2013-02-482919 · Cited by 75
PK Assays for Antibody–Drug Conjugates: Case Study with Ado-Trastuzumab Emtansine
Dere, R. C., Yi, J., Lei, C., et al. (2013) · Bioanalysis · doi:10.4155/bio.13.72 · Cited by 75
Cohen, R., Vugts, D. J., Visser, G. W. M., van Walsum, M., Bolijn, M., Spiga, M., Lazzari, P., Shankar, S. P., Sani, M., Zanda, M., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1141 · Cited by 73
Loke, J. C. T., Khan, J. N., Wilson, J. S., Craddock, C., & Wheatley, K. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2218-6 · Cited by 71
Identification of the sites of IgG catabolism in the rat
Henderson, L. A., Baynes, J., & Thorpe, S. R. (1982) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(82)90272-7 · Cited by 69
Petersen, B. H., Deherdt, S. V., Schneck, D. W., & Bumol, T. F. (1991) · PubMed · Cited by 66
Govindan, S. V., Cardillo, T. M., Rossi, E. A., Trisal, P., McBride, W. J., Sharkey, R. M., & Goldenberg, D. M. (2014) · Molecular Pharmaceutics · doi:10.1021/mp5006195 · Cited by 62
What Happened to Anti-CD33 Therapy for Acute Myeloid Leukemia?
Jurcic, J. G. (2011) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-011-0103-0 · Cited by 62
Niwa, R., & Satoh, M. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24316 · Cited by 61
CC‐1065とデュオカルマイシン 新種の天然誘導DNAアルキル化剤のかぎの解明
Boger, D. L., & Johnson, D. S. (1995) · Proceedings of the National Academy of Sciences · Cited by 60
Perez, E. A., Hurvitz, S. A., Amler, L. C., Mundt, K., Ng, V., Guardino, E., & Gianni, L. (2014) · Breast Cancer Research · doi:10.1186/bcr3661 · Cited by 58
Naumovski, L., & Junutula, J. R. (2010) · PubMed · Cited by 56
Lorvotuzumab mertansine: antibody-drug-conjugate for CD56⁺ multiple myeloma
Berdeja, J. G. (2014) · Frontiers in bioscience · doi:10.2741/4202 · Cited by 46
Jagannath, S., Chanan-Khan, A., Heffner, L. T., Avigan, D., Zimmerman, T. M., Lonial, S., Lutz, R. J., Engling, A., Uherek, C., Osterroth, F., et al. (2011) · Blood · doi:10.1182/blood.v118.21.305.305 · Cited by 44
An Overview on the Development of New Potentially Active Camptothecin Analogs Against Cancer
Chazin, E. D. L., Reis, R. D. R., Junior, W., et al. (2014) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557514666141029233037 · Cited by 40
Jackson, D., & Stover, D. R. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1536-7 · Cited by 34
Development and Activities of the BR96-Doxorubicin Immunoconjugate
Hellström, I., Hellström, K. E., & Senter, P. D. (2003) · Humana Press eBooks · doi:10.1385/1-59259-114-0:3 · Cited by 20
Goff, L. W., Papadopoulos, K. P., Posey, J. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.e15625 · Cited by 18
Kurkjian, C. D., LoRusso, P. M., Sankhala, K. K., Birrer, M. J., Kirby, M. W., Ladd, S., Hawes, S. J., Running, K. L., O’Leary, J. J., & Moore, K. N. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.2573 · Cited by 18
Brentuximab Vedotin for the Treatment of Patients with Hodgkin Lymphoma
Younes, A. (2013) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2013.10.005 · Cited by 16
Gordon, M. S., Gerber, D. E., Infante, J. R., Xu, J. M., Shames, D. S., Choi, Y., Kahn, R. S., Lin, K., Wood, K., Maslyar, D. J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.2507 · Cited by 14
Liu, J. F., Moore, K. N., Birrer, M. J., Berlin, S. T., Matulonis, U. A., Infante, J. R., Xi, J., Kahn, R., Wang, Y., Wood, K., et al. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-lb-290 · Cited by 12
Cited by
Senescent cells: an emerging target for diseases of ageing
Childs, B. G., Gluscevic, M., Baker, D. J., Laberge, R.-M., Marquess, D., Dananberg, J., & van Deursen, J. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.116 · Cited by 1,284
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754
Srinivasarao, M., & Low, P. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00013 · Cited by 605
Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?
Staudacher, A. H., & Brown, M. P. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.367 · Cited by 540
Nakada, T., Sugihara, K., Jikoh, T., Abe, Y., & Agatsuma, T. (2019) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c18-00744 · Cited by 442
Metadata
- Authors
- Polakis, P.
- Venue
- Pharmacological Reviews
- Publisher
- Elsevier BV
- Published
- 2016-01
- Volume
- 68
- Issue
- 1
- Pages
- 3-19
- ISSN
- 0031-6997 (ISSN-L)
- OpenAlex
- W2179836657
- Cited by
- 307
- References
- 107
- FWCI
- 33.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.